Explore Dexcom's Q2 2025 financial report highlighting 15.2% revenue growth and a $750M share repurchase plan. A compelling buy for investors in the CGM market.
Explore Dexcom, Inc.'s latest 8-K report filed on May 8, 2025, revealing vital updates in the medical tech sector. Stay informed on significant events affecting DXCM stock.
Explore Dexcom, Inc.'s latest 8-K filing details, stock info, and significant updates for May 1, 2025. Essential for investors and stakeholders.
Explore Dexcom's Q1 2025 financial performance with a 12.5% revenue growth but declining net income. Key insights for investors on profitability and future strategies.
Explore DexCom, Inc.'s 2024 financial report showcasing impressive revenue growth, effective cost management, and strategic R&D investments in the diabetes management market.
Explore Dexcom, Inc.'s 8-K report filed on February 13, 2025, detailing significant corporate events impacting stock DXCM. Essential reading for investors.